Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome  by Virmani, Pooja et al.
Hematopoietic Stem Cell
Transplant for Mycosis
Fungoides and Se´zary
Syndrome
Pooja Virmani, MBBS, MDa,1, Jasmine Zain, MDb,1, Steven T. Rosen, MDb,
Patricia L. Myskowski, MDa, Christiane Querfeld, MD, PhDb,c,d,*KEYWORDS
 Cutaneous T-cell lymphoma  Mycosis fungoides  Se´zary syndrome
 Autologous hematopoietic stem cell transplant  Allogeneic hematopoietic stem cell transplant
 Myeloablative  Reduced-intensity conditioning
KEY POINTS
 Autologous transplant has low treatment-related complications in mycosis fungoides (MF)/Se´zary
syndrome (SS), but high relapse rates.
 Allogeneic transplant has curative potential in MF/SS with lower relapse rates and improved
survival.
 Allogeneic transplant induces an immune-mediated graft-versus-lymphoma (GvL) effect in MF/SS.
 Myeloablative conditioning (MAC) in MF/SS is associated with higher risk of treatment-related tox-
icities and acute graft-versus-host disease (GVHD) and is limited to younger and medically fit
patients.
 Reduced-intensity conditioning (RIC) in MF/SS shows lower treatment-related complications and is
increasingly used in older patients with comorbidities.
 There is no difference in chronic GVHD between MAC and RIC.
 Relapses following allogeneic transplant respond to GvL effect induced by decreased immunosup-
pression and donor lymphocyte infusion (DLI).INTRODUCTION
Primary cutaneous T-cell lymphomas (CTCL)
represent a heterogeneous group of non–Hodgkin
lymphomas (NHLs) that manifest in the skin with
no evidence of extracutaneous disease at theFunding sources: none.
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Virmani et al808patients present with advanced stage (generally
considered to be stage IIB and higher) and another
25% progress into higher stage in the course of
their disease.1–3 SS is the leukemic and most
commonly encountered type of aggressive CTCL.1
Most patients with early-stage MF respond well
to skin-directed therapies with reported long-term
remissions. Treatment for patients with advanced
disease includes various combinations of skin-
directed therapies, biologic response modifiers,
histone deacetylase (HDAC) inhibitors, investiga-
tional agents, as well as single-agent and/or multi-
agent chemotherapy regimens.4,5 None of these
treatment options have been shown to prolong
disease-specific survival or overall survival (OS)
and often lead to short-term disease control with
a median survival ranging from 1.4 to 4.7 years in
patients with advanced stages (IIB–IVB) of MF
and SS.6 Borrowing from the paradigm of aggres-
sive lymphomas, hematopoietic stem cell trans-
plant (HSCT) has been explored as a treatment
option in patients with advanced-stage MF/SS
and other subtypes. The data for using high-dose
therapy and autologous HSCT (ASCT) remain
disappointing, but the results of allogeneic stem
cell transplant are encouraging for the treatment
of CTCL. The data series are small, and there is lit-
tle consensus on conditioning regimens and other
aspects of the transplants that are largely driven
by institutional preferences. This article discusses
the role of allogeneic stem cell transplant in the
care of patients with CTCL and presents relevant
data to support its use.OVERVIEW OF HEMATOPOIETIC STEM CELL
TRANSPLANT
HSCT, formerly known as bone marrow transplant
(BMT), is a medical procedure in which multipotent
stem cells derived from the bone marrow, periph-
eral blood, or umbilical cord are infused into a pa-
tient for treatment of hematological disorders and
malignancies. This procedure requires that the pa-
tient’s own hematopoietic and immune function be
suppressed enough to accept the infused cells and
allow homing of these cells to the marrow spaces
and establishment of a donor-derived hematopoi-
etic system in the host. This procedure can be
accomplished either by chemotherapy alone or
by combination of chemotherapy with radiation
therapy called conditioning or preparative regimen
given before stem cell infusion. The establishment
of a donor-derived hematopoietic system requires
some time duringwhich the patient remains pancy-
topenic and entirely depends on supportive mea-
sures to prevent and treat the complication of
pancytopenia as well as the conditioning regimen.The stem cells can be derived from the patient’s
own hematopoietic system (autologous) or from
an HLA-matched donor (allogeneic) who can be a
sibling (related) or a matched unrelated donor.
Other sources now extend to haploidentical family
members and cord blood stem cells and are dis-
cussedbelow.Major indications for stemcell trans-
plant include hematologic malignancies such as
leukemia, lymphoma, multiple myeloma, and other
myeloproliferative disorders. According to theCen-
ter for International Blood and Marrow Transplant
Research (CIBMTR) data, approximately 12,000
autologous and 8000 allogeneic transplants were
performed in the year 2013 and the numbers are
increasing.7STEM CELL SOURCES
Hematopoietic stem cells express properties of
multipotency and self-renewal and reside in bone
marrow niches supported by cytokines and other
microenvironmental factors. Human hematopoietic
stem cells express CD34, CD38, CD90, CD133,
CD105, CD45, and also c-kit (CD117), the receptor
for stem cell factor, and these cells test negative for
the markers that are used for the detection of line-
age commitment. Historically, stem cell collection
was performed in the operating roomunder general
anesthesia using a large trocar to collect bone
marrow from the pelvic bones in adults and long
bones in children. This procedure has now given
way to peripheral blood as a source of stem cells
throughaprocesscalled apheresis.8 Theperipheral
blood stem cells can be mobilized into the circula-
tion either by chemotherapy (in case of autologous
collections) or by injections of hematopoietic
growth factors, that is, granulocyte colony-
stimulating factor supplementedbyCXR4 inhibitors
such as plexiafor,9 and collected. Most autologous
stem cells are cryopreserved in dimethyl sulfoxide
before infusion in contrast to allogeneic stem cells
that are usually infused fresh on the day of collec-
tion.Umbilical cordblood (UCB),which is rich in he-
matopoietic stem cells, can be cryopreserved and
used in an appropriate patient. However, because
a cord can yield only small amounts of blood
(approximately 50 mL), a single cord can only pro-
vide adequate stem cells for a child or small adult.
Generally, 2 UCB units need to be combined for
adult transplants, and there is now a significant
body of data to support the safety and efficacy of
this approach.DONOR SELECTION
HLA typing is required to match a donor and recip-
ient for allogeneic stem cell transplants. The major
Transplant for Mycosis Fungoides and Sezary Syndrome 809HLA genes fall into 2 categories (Type I and Type
II), and serologic and molecular matching is per-
formed on the basis of variability at 6 loci of the
HLA gene. A perfect match at these loci is desir-
able to ensure engraftment and prevent complica-
tions of GVHD. Mismatches of the Type I genes (ie,
HLA-A, HLA-B, or HLA-C) increase the risk of graft
rejection. A mismatch of an HLA Type II gene (ie,
HLA-DR, or HLA-DQB1) increases the risk of
GVHD. Molecular methods are increasingly being
used to increase the accuracy of tissue typing to
ensure optimal matching. Sibling donors have a
25% chance of being a match with the recipient.
Rarely, patients have a syngeneic donor, that is,
a monozygotic twin who is perfectly matched at
all HLA loci. Most other patients need to rely on
an unrelated HLA-matched donor who may be
found through the National Marrow Donor Pro-
gram and other such worldwide registries.10
Unfortunately, these registries have marked un-
derrepresentation of specific ethnic and minority
racial groups. This underrepresentation has driven
the need to look for alternative donors. A haploi-
dentical donor is a partially matched first-degree
relative of the patient (child, parent, or sibling).11
The advantage of haploidentical transplant is im-
mediate and permanent availability of the donor
for current and future therapies. Initially, the 3 an-
tigen mismatches in these transplants led to unac-
ceptably high transplant-related toxicity, but with
the use of T-cell depletion techniques, improved
immunosuppression, and supportive care, haploi-
dentical transplants are increasingly being offered
to patients who lack an HLA-matched donor.12
Umbilical cords provide immunologically naive
stem cells and a reduced risk of GVHD and are a
relatively accessible source of stem cell trans-
plants. The main disadvantage is the small number
of stem cells that may by themselves be inade-
quate in number for successful engraftment in an
adult. Ex vivo expansion, double cord transplants,
and combined haploidentical and cord transplants
have resulted in improved outcomes for these pa-
tients.13,14 According to the European Bone
Marrow Transplant Registry survey of 2013, as
many as 43% of all HSCTs done that year were
allogeneic and there was a notable increase in
the use of alternate donors.15CONDITIONING REGIMENS
Thepreparative regimengivenbefore stemcell infu-
sion is called a conditioning regimen and has a 2-
fold purpose depending on the type of transplant.
In the case of an autologous stem cell transplant,
the conditioning regimen consists of chemotherapy
with or without radiation and is designed to give ahigh dose of antitumor therapy for cytotoxic pur-
poses. The hematopoietic system damaged by
chemotherapy is then reconstituted with trans-
planted autologous stem cells. The state of immu-
nosuppression created by the conditioning
regimen improves with time, and the patient does
not have anyGVHD. In allogeneic transplant, condi-
tioning treatment is required for engraftment and
prevention of GVHD by suppressing host immunity
in addition to antitumor effects. Regimens can be
fully MAC for maximal antitumor effects and gener-
ally include high-dose cytoxan, busulfan, high-dose
etoposide, and/or total body irradiation (TBI). These
regimens can have significant immediate toxicity
that can contribute to significant regimen-related
morbidity andmortality in the immediate posttrans-
plant period.16,17 Nonrelapse mortality (NRM) of
22% was reported in a cohort of 60 patients with
advanced CTCL (clinical stage IIB–IVB) treated
with allogeneic stem cell transplant. In multivariate
analysis, MAC was associated with a higher NRM
(hazard ratio, 4.5;P5 .1)18 RICor nonmyeloablative
transplants are less cytotoxic and mostly immuno-
suppressive, resulting in decreased immediate
transplant-related toxicity and allowing older and
more frail patients to undergo transplant.19 These
regimens consist of purine analogs such as fludara-
bine and cladribine aswell as low-dose TBI and rely
on theGVHDeffect for their antitumoreffects. These
regimensare associatedwithdecreased immediate
transplant-related toxicity and less-acute GVHD,
but there has been no change in the incidence of
chronic GVHDwith RIC.20 Use of RIC has extended
the use of allogeneic stem cell transplants to pa-
tients into their 70s and 80s if they are otherwise in
good health. CIBMTR data confirm the increasing
use of RIC for allogeneic stem cell transplants and
the increasing age of transplant recipients in the
United States.15COMPLICATIONS
Several complications are associated with HSCT
dependingon the typeof conditioning, typeof trans-
plant, and engraftment phase.21 Themost common
cause of transplant-related morbidity and mortality
is GVHD, followed by infections. GVHD remains a
challenge in the care of patients undergoing alloge-
neic stem cell transplant. Classically, acute GVHD
occurs within the first 100 days of transplant and
manifests itself primarily in the skin, gastrointestinal
tract, and liver. However, the development of
various conditioning regimens and the use ofDLI af-
ter transplant have changed the time course and
presentation for acute and chronic GVHD.
The pathogenesis of acute GVHD is initiated
by recipient tissue damage occurring from
Virmani et al810conditioning regimen leading to release of inflam-
matory cytokines that lead to the expansion of
donor lymphocytes following contact with host
and donor antigen-presenting cells that express
disparate antigens resulting in alloreactive T cells
that induce tissue damage. The incidence of acute
GVHD varies from 20% to 70% and is directly
related to the degree of mismatch between HLA
proteins. The incidence ranges from 35% to 45%
in recipients of full-matched sibling donor grafts
to 60% to 80% in recipients of one-antigen HLA-
mismatched unrelated donor grafts. The same de-
gree of mismatch causes less GVHD using UCB
grafts, and the incidence of acute GVHD is lower
following the transplant of partially matched UCB
units and ranges from 35% to 65%.22 Chronic
GVHD is the major cause of late nonrelapse death
following transplant. Older recipient age and a his-
tory of acute GVHD are the greatest risk factors for
chronic GVHD. Incidence ranges from 60% to
80%, and manifestations of chronic GVHD are
protean and often resemble an autoimmune disor-
der.22 The National Institutes of Health proposed
standard criteria in 2005 for diagnosis, organ
scoring, and global assessment of chronic GVHD
severity to establish a common platform for sub-
classifying chronic GVHD.23
Prevention strategies using immunosuppressive
agents including calcineurin inhibitors, metho-
trexate, mammalian target of rapamycin inhibitors,
or novel agents begin before stem cell infusion
and are maintained for some time after allogeneic
transplant. Treatment of GVHD is initiated when
any sign of GVHD appears and consists of high-
dose steroids and other strategies for immuno-
suppression. Prolonged immunosuppression
delays immune reconstitution of the host and in-
creases the risk of serious infections leading to
high morbidity and mortality rates. Other compli-
cations after stem cell transplant can be related
to conditioning regimens causing end-organ
toxicity, secondary malignancies, and psychoso-
cial issues related to chronic medical problems.
Even with improved supportive care measures,
there is a significant morbidity and mortality asso-
ciated with stem cell transplant, which in the case
of allogeneic stem cell transplants can range from
20% to 40% depending on the patient’s comor-
bidities, donor type, degree of HLA mismatch, un-
derlying disease, and conditioning regimen.24
Autologous stem cell transplants are associated
with a much lower risk of death at less than 5%
in most centers, but there is a higher incidence
of disease relapse. When determining the eligi-
bility for HSCT, these risks have to be weighed
against the risk of death and morbidity posed by
the disease.GRAFT-VERSUS-LYMPHOMA EFFECT
The existence of an immunologic GvL reaction
associated with allogeneic stem cell transplant is
well established.25,26 Allogeneic transplant is suc-
cessful partly because of the GvL effect of the
donor graft, independent of the conditioning
regimen. Evidence for GvL effects is based on
the following criteria: RIC resulting in long-term
disease control, increased risk of relapse associ-
ated with T-cell depletion, withdrawal of immuno-
suppression, use of DLIs to eradicate documented
disease relapse after allogeneic transplant, and
association of disease control with GVHD. A GvL
effect against CTCL has been established and is
discussed in later sections.AUTOLOGOUS STEM CELL TRANSPLANT FOR
MYCOSIS FUNGOIDES AND SE´ZARY
SYNDROME
High-dose therapy and ASCT have curative poten-
tial in aggressive chemotherapy-sensitive relapsed
lymphomas. Using similar approaches, ASCT has
been performed in cases of advanced CTCL in or-
der to establish long-term remissions. Condition-
ing regimens have incorporated high-dose
chemotherapy either with or without TBI. Some in-
vestigators have reported the use of total skin
electron beam (TSEB) therapy to provide improved
control of skin disease in patients with CTCL
before initiating ASCT and avoid the generalized
organ toxicity of TBI. Bigler and colleagues27 first
reported on 6 patients with MF who underwent
TBI or TSEB-based regimens followed by ASCT:
5 patients achieved complete remission (CR) but
3 showed relapse in less than 100 days, whereas
2 remained in persistent CR after 1 year. Results
demonstrated that the procedure was feasible,
and increased transplant-related mortality (TRM)
or transplant-related morbidity was not reported
for these patients. A few other case reports
showed early relapses within the first 100
days.28–31 The largest series by Ingen-Housz-Oro
et al32 reported on 10 patients with CTCL that
included 1 patient with MF; 8 patients with periph-
eral T-cell lymphoma (PTCL), unspecified (PTCL,
not otherwise specified [NOS]); and 1 patient with
subcutaneous panniculitis-like T-cell lymphoma
including patients with systemic disease in addi-
tion to skin manifestations. Conditioning was TBI
based and 7 of 10 patients achieved a CR. Howev-
er, in 6 patients, the condition relapsed in less than
4 months and in 1, it relapsed at 7 years (PTCL,
NOS). Remaining patients experienced fatal pro-
gression. Of note, some of the relapses responded
to local and biologic therapies.
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and colleagues33 on 9 patients with MF consisting
of 5 patients with stage IIB and 4 patients with
stage IVA disease; 8 patients demonstrated a T-
cell clone in the peripheral blood. This study was
a pilot study of T-cell depletion and ASCT in these
patients using double CD34-positive and CD4/
CD8-negative selection by immunomagnetic
methods. TBI was given to only 2 patients, and
the others were conditioned with chemotherapy
only. Of the 9 patients, the condition relapsed in
7 patients at a median of 7 months, mostly with
limited disease that responded to conventional
therapy; 4 patients were analyzed for T-cell recep-
tor rearrangement after transplant and had detect-
able clone before or at the time of relapse. There is
one report of a patient with SS receiving autolo-
gous HSCT.28 This patient was conditioned with
the combination of chemotherapy and TBI. He
showed relapse after 3 months and died after
15 months of infectious complications. Moreau
and colleagues34 reported successful transplant
in 1994 on 4 cases of CTCL other than MF/SS
(including 2 patients with a CD301 lymphoprolifer-
ative disorder [CD30 1 LPD]) using a TBI-based
regimen with CR at 22, 41, 46, 44, and 51 months.
This report predates the 2008 World Health Orga-
nization classification, and it is unclear from the
publication whether patients were diagnosed
with primary cutaneous anaplastic large cell lym-
phoma (PCALCL) or lymphomatoid papulosis or
both. No specific data are available for the use of
ASCT in large cell transformation (LCT)-MF,
although these cases tend to be treated as sys-
temic T-cell lymphomas and are likely included in
the series of transplants for systemic diseases.
These limited data show that ASCT is feasible,
but in most cases, the responses are not sustained
except possibly for CD30 1 LPD; however, these
entities have already a favorable long-term
outcome without the need of aggressive thera-
pies.1 The duration of remission does not seem
to be related to the stage of the disease or the
absence of a detectable T-cell clone in the harvest.
Although the numbers are very small, the use of
TBI did not seem to predict improved outcomes.
These early relapses point to the inability of high-
dose therapy to control disease pointing to the
need for improved targeted therapies. However,
some of the relapses seemed to be less aggres-
sive and could be managed with local and biologic
therapies for a while. The use of high-dose therapy
and ASCT has essentially been abandoned with a
belief that this is not a curative approach and that
the inherent chemoresistance of these tumors
contributes to the low success rate of this
approach.ALLOGENEIC STEM CELL TRANSPLANT FOR
MYCOSIS FUNGOIDES AND SE´ZARY
SYNDROME
Allogeneic stem cell transplant has been shown to
achieve durable CRs and provide long-term remis-
sions and a potentially curative treatment option in
CTCL through a proposed GvL. One of the earliest
allogeneic transplants was reported by Koeppel
and colleagues35 in 1994 and supported the feasi-
bility of the procedure in spite of the general state
of immunosuppression and compromised skin
barrier in these patients. Several case reports
and series have been published since then as indi-
cated in Table 1.18,36–46 However, the experience
of allogeneic transplant for treatment of MF/SS is
limited to small retrospective studies with small
number of patients usually lumped together with
transplant data for subtypes of T cell and other
NHL. The following discussion attempts to tease
out data specific to CTCL and its subtypes.
There are no prospective studies for allogeneic
stem cell transplants in CTCL. In 2005, the City of
Hope Comprehensive Cancer Center published
the first larger single-center retrospective series
of allogeneic stem cell transplant in 8 patients
with advanced MF/SS (IIB 5 1, IVA 5 7) including
1 patient with transformed MF and 4 patients
with SS.36 Patients were heavily pretreated with a
median of 7 treatments before transplant including
skin-directed therapies. A total of 4 patients
received full-intensity conditioning, whereas the
remaining 4 received fludarabine- and melphalan-
based RIC regimens. All patients achieved com-
plete clinical and molecular remission after
transplant within 2 months; 6 of 8 had durable
remission and were alive at a median follow-up of
7 years, and 1 patient with SS died of chronic
GVHD and another with tumor MF died of respira-
tory syncytial virus pneumonia with a TRM of 25%.
At a median follow-up of 56 months, 6 of 8 were
alive with no evidence of disease. Even though
the numbers were small, there seemed to be no
difference in outcome based on intensity of condi-
tioning and TBI seemed to be associated with
increased skin toxicity in the posttransplant period.
A large multicenter center study from the Euro-
pean Bone Marrow transplant registry reported on
a 10-year allotransplant experience of 60 patients
with advanced MF (n 5 36, 20 stage IV and 16
with IIB/III) and SS (n 5 24) by Duarte and col-
leagues.18 In this study, 73% (44/60) received
RIC, 27% had MAC, and 42% (25/60) had T-cell
depletion before transplant. Patientswere followed
up for amedianof 7 yearswith the longest follow-up
being of 12 years. There was no significant differ-
ence in outcome for patients with MF and SS. An
Table 1
List of larger case series and retrospective studies on allogeneic transplant in patients with MF/SS
Reference
No of
Patients
Patient
Characteristics
Conditioning
Regimen Follow up OS (2 y/5 y) PFS Relapse Rate Morbidity Mortality
Molina
et al,36
2005
8 4 MF (IIB 5 1;
IVA 5 3)
4 SS (IVA 5 4)
4 MAC
4 RIC
4 HLA-matched
sibs
4 unrelated
donors
56 mo — — — — 25% (2/8) died
1/2: chronic GVHD
1/2: RSV
pneumonia
Wu et al,37
2009
20 14 MF (IB 5 1,
IIB 5 3,
IVA 5 10)
6 SS (IIIA 5 1,
IVA 5 5)
9 MAC
11 RIC
38 mo 1-y OS: 85%
5-y OS: 80%
1 y: 65%
5 y: 60%
25% (5/20): re psed (2
in MAC and in RIC)
75% (15/20):
GVHD
20% (4/20) died
2/4: infection
2/4: GVHD (similar
in MAC and RIC)
Duvic
et al,38
2010
19 8 MF (IIB 5 3,
IVA 5 4,
IVB 5 1,
LCT 5 2)
11 SS (IVA 5 2,
IVB 5 9,
LCT 5 6)
19/19 RIC
15/19 TSEB
1.7 y 2-y OS: 79% 2 y: 53% 39%: relapse
Median time d
(28–718 d)
67% acute GVHD
67% chronic
GVHD
31.5% (6/19) died
4/6 in CR
2/6 died of
progressive
disease
Paralkar
et al,39
2012
12 5 MF (IIB 5 2,
IIIB 5 1,
IVA2 5 1,
IVB 5 1,
LCT 5 1)
4 SS (IVA1 5 1,
IVA2 5 3,
LCT 5 1)
3 GDTL
10/12 RIC
2/12 MAC
15 mo (all
patients)
22 mo (alive
patients)
2-y OS 58%
Median
OS 37 m
Median
PFS 5.3 m
— 40% (4/10) sh wed
relapse
2/4 reachieve CR
with DLI/
decreased
immunosup ression
75 acute GVHD 17% died of sepsis
and active
disease
Shiratori
et al,40
2014
9 7 MF (IIB 5 2,
IVA2 5 4,
IVB 5 1)
2 SS (IIB, IVA2)
LCT 5 8
RIC — 3 y OS: 86% 3 y: 44% 56% (5/9)
(80% only in in)
11%: acute GVHD
67%: chronic
GVHD
—
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Duarte
et al,18
2014
60 36 MF
24 SS
IIB 5 3
III 5 13
IVA 5 31
IVB 5 13
73% RIC
27% MAC
7–12 y 1 y: 66%
5 y: 46%
7 y: 44%
5 y: 32%
7 y: 30%
45% (27/60) had
relapse at 4 m
8/27: alive at 8 y
— 22% NRM
Polansky
et al,41
2015
13 (217) 13 SS (IVA 5 3,
IVB 5 10)
TSEB: 13/16 — — — — 69%: acute GVHD
44%: chronic
GVHD
46% (11/24)
77% (8/11) died
shortly
due to
complications
de Masson
et al,42
2014
37 5 MF
1 FMF
5 SS (IIB 5 11,
IIIA 5 2,
IVA1 5 2,
IVA2 5 11,
IVB 5 5)
19 LCT-MF
(IIB 5 7,
IIIA 5 1,
IVA2 5 9,
IVB 5 2)
1 LCT-SS (IVA1)
5 PCALCL
1 PTCL, NOS
12 MAC
25 RIC
29 mo 57% — 51%
 In first year
 Mostly in skin
 50% as less-severe
form
59% acute
cutaneous
GVHD
18%
Lechowicz
et al,43
2014
129 Registry data 83/129 RIC
46/129 MAC
32–39 mo 1 y: 54%
5 y: 32%
No difference
between
MAC & RIC
1 y: 31%
5 y: 17%
1 y: 50%
5 y: 61%
41% acute GVHD
43% chronic
GVHD at 3 y
1 y: 19%
5 y: 22%
No difference
between
AC & RIC
Abbreviations: FMF, folliculotropic MF; GDTCL, gamma delta T-cell lymphoma; PFS, progression-free survival; RSV, respiratory syncytial virus.
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Virmani et al814OS of 44% was reported at 7 years with a
progression-free survival (PFS) of 30%. About
45% patients showed relapse at a median of
3.8 months with only 2 relapses occurring later
than 2 years after transplant. All but one patient
with relapse achieved CR with DLI and/or salvage
therapies. The NRM at 7 years was 22% with all
deaths occurring within 14 months of transplant.
The investigators concluded that advanced-
phase disease and T-cell depletion were associ-
atedwith increased riskof relapseandprogression.
Patientswith lowperformance scores before trans-
plant and those receiving MAC had higher NRM.
Transplant from unrelated donors had a marginal
effect on NRM, but the PFS and OS were signifi-
cantly reduced when compared with related do-
nors. Finally, RIC had better OS (63% vs 29% at
3 years) and lower NRM (14% vs 49%) when
compared with MAC with no significant difference
in the relapse rates. The series identified disease
status, type of conditioning, and donor type as
the main factors affecting the outcome of alloge-
neic transplant in MF/SS.
Duvic and colleagues38 have reported the
largest single-center study using reduced-
intensity allogeneic transplant in 19 patients (me-
dian age 50 years) with advanced MF/SS. There
were 3 patients with stage IIB MF, 2 with IVA/B
MF, and 14 patients with SS as determined by
the worst stage before transplant; 8 patients had
LCT including 3 with CD30 1 LCT. Of note, in this
study, TSEB was used in 15 patients to improve
control of skin disease along with the conditioning
regimen that was based mostly on fludarabine and
melphalan. The CR rate of 58% was similar to the
60.5% rate reported by Duarte and colleagues.18
At the end of the median follow-up period of
1.7 years, 13 patients (68%) were alive with 11
were in complete clinical and molecular remission.
Patients in whom the condition relapsed were
treated with DLI and/or tapering immunosuppres-
sion to induce secondary remission. Of the 6 pa-
tients who died, 4 were in CR; 2 patients with SS
died due to progressive disease and acute
GVHD, precluding treatment with DLI. Sex, stem
cell source, and SS were not predictive of relapse
or OS (79% at 2 years). The study concluded that
TSEBT combined with reduced-intensity alloge-
neic HSCT is an effective treatment option in
advanced MF/SS. Subsequently, there have been
several studies further exploring the role of RIC
with allogeneic transplant in MF/SS. In 2014, Shir-
atori and colleagues40 reiterated the role of alloge-
neic transplant in downstaging the lymphoma in
subsequent relapses with significantly low NRM
rates associated with RIC. Shorter duration of
remission was, however, noted by Herbert andcolleagues44 in 3 patients with advanced-stage re-
fractory disease treated with reduced-intensity al-
lografts. The relapses responded to DLI and
reduction in immunosuppression, but the
response was not sustained. One of them showed
relapse with high-grade disease and another died
of chronic GVHD. The investigators concluded
that GvL effect is insufficient for high-grade dis-
ease and that reduced-intensity allografting should
be considered early in the disease course with
prior tumor debulking preferably with prior ASCT.
Other notable studies include the report from the
French Study Group on Cutaneous Lymphomas by
de Masson and colleagues.42 Their multicenter
retrospective analysis included 37 patients with
advanced MF. Patient characteristics were as fol-
lows: 31 patients had MF or SS including 20 (54%)
with LCTwith 10 cases of CD30-positive LCT; 5 pa-
tients hadPCALCL including 3 cases that were ALK
(anaplastic lymphoma kinase)-1 negative, 1 alk-
positive case, and 1 alk-unknown case. All patients
with epidermotropic T-cell lymphoma had failed
skin-directed therapies; 22(59%) had received
combination chemotherapy.
Both MAC (32%) and RIC (68%) were used for
these patients. Relapse rate was high in this group
of patients with advanced disease. The 2-year
estimated PFS was 31% and OS was 57%. In
this study, the use of antithymocyte globulin signif-
icantly reduced PFS (P 5 .01) in univariate and
multivariate analysis. Lechowicz and colleagues43
have published the outcomes of allogeneic trans-
plant in 129 patients with CTCL, diagnosed with
MF/SS and reported to CIBMTR between 2000
and 2009. Most (64%) patients received nonabla-
tive conditioning or RIC. PFS at 1 year and 5 years
was 31% and 17%, respectively, and was lower
than that reported by Duarte and colleagues18;
the NRM of both the studies were similar (22% at
5 years). The study, however, concluded that the
conditioning intensity did not have any impact on
NRM or OS, unlike the previous study. The relapse
rate was quite high with most relapses occurring
within the first year of transplant (50% at 1 year
and 61%at 5 years). The study did not differentiate
between outcomes for patients with MF and SS.
Overall, the results of allogeneic transplant are
encouraging when compared with autologous
transplant and conventional treatment options in
terms of sustained remission and high rates of
PFS and OS after the procedure. A comparison
done by Wu and colleagues37 in 2009 revealed a
5-year OS of 80% in allogeneic versus 23% in
autologous transplant group with similar clinical
characteristics in both groups. While 60% re-
mained disease free at 5 years postallogeneic
transplant, all patients in the autologous group
Transplant for Mycosis Fungoides and Sezary Syndrome 815showed relapse at a median of 2.5 months (range
1–14 months). In this meta-analysis, most patients
(70%) had persistent GVHD after receiving alloge-
neic transplant for the treatment of MF/SS.37 All 4
patients with myeloablative allogeneic transplant
treated by the group at City of Hope developed
relatively severe acute GVHD progressing into
chronic disease, whereas none of the patients in
the reduced-intensity group developed acute
GVHD greater than grade 2. One of the patients
in the myeloablative group eventually died
because of complications of treatment of
GVHD.36 Duvic and colleagues38 reported GVHD
in 62% patients treated with reduced-intensity
allogeneic transplant. The disease was, however,
noted to be less severe as a result of prior tumor
debulking with TSEBT, leading to only 1 GVHD-
related death. Similar rates of GVHD were re-
ported by de Masson and colleagues42; however,
no difference was noted between the different
conditioning regimens.
The high rates of NRM because of GVHD and in-
fections associated with myeloablative regimens
have improved with the use of reduced-intensity
and nonmyeloablative regimens, which have been
proved to be equally efficacious if used early in
the disease at a low tumor bulk. Advanced-phase
disease has been suggested as an independent
adverse factor for relapse in various studies.18,44
The outcomes of these studies highlight the fact
that reduced-intensity transplants are promising
and merit further investigation. Strategies such as
pretransplant tumor bulk reduction with TSEBT or
prior autologous transplants can be used to pro-
vide additional benefit and to avoid the toxicity
associated with full-dose myeloablation in patients
with high-grade disease.
The selection of the appropriate patient for
transplant still remains challenging with no unifying
criteria except physician judgments.SUMMARY AND FUTURE DIRECTIONS
Cutaneous lymphomas remain clinically chal-
lenging, and many patients show a slowly pro-
tracted indolent course that would never require
a stem cell transplant for disease control. For
advanced-stage MF with relapse/refractory dis-
ease or aggressive subtypes such as SS, stem
cell therapy needs to be considered. ASCT has
been largely abandoned because of high numbers
of early relapses, whereas allogeneic HSCT has
shown to result in complete clearance of skin le-
sions, blood involvement, and other evidence of
disease with some patients achieving long-term
remissions. GvL effect has been demonstrated
by the successful use of RIC regimens, use ofDLI, and withdrawal of immunosuppression in
cases of disease relapse after transplant. Although
most studies are small, with marked heterogenic-
ity in treated disease stage, histology, prior thera-
pies, and transplant-related procedures, the
outcome data do not suggest any difference be-
tween MF or SS and the numbers for other sub-
types are too small to draw any conclusions.
There is no consensus about the degree of remis-
sion needed before transplant for a successful
outcome. Both related and unrelated matched do-
nors have been used, and there are now support-
ing data using cord blood as a source of stem
cells. There is still no consensus on conditioning
regimens, but remissions have been achieved us-
ing RIC even in patients with advanced and refrac-
tory disease states indicating that the intensity of
the conditioning regimen may not be required for
response. TSEB before transplant may be associ-
ated with improved skin control. Relapses still
occur after allogeneic transplants but have been
treated successfully with adjustment of immuno-
suppression, DLI infusion, or skin-directed treat-
ments. The use of allogeneic stem cell transplant
is associated with higher incidence of complica-
tions including GVHD, infections, and death.
At present, there are no clear guidelines to
select appropriate patients for stem cell trans-
plant. Historical data have suggested that trans-
plant has been performed for patients who have
required multiple lines of systemic therapy after
failing skin-directed therapies, especially combi-
nation chemotherapy, usually with tumor stage/
nodal or systemic disease. However, the approval
of new targeted therapies for CTCL including
HDAC inhibitors and other targeted therapies
now allows for more patients to be treated and
maintained on noncytotoxic therapies. Talpur
and colleagues47 have published improved out-
comes in patients with MF and SS at all stages
including improved PFS and OS. The use of ge-
netic profiling and gene sequencing is likely to
allow better prognostic characterization of these
tumors beyond clinical features of LCT and histo-
logic subtype and may allow better selection of
patients who require transplant for disease
control.48
As with other hematologic malignancies, dedi-
cated transplant protocols should be developed
in multicenter trials to address the needs of pa-
tients with CTCL with improved conditioning re-
gimes and supportive care measures. In addition,
transplant physicians need to be aware of the
unique disease features of patients with the
various types of CTCL and need to develop strate-
gies for improved disease control to prevent re-
lapses and reduce posttransplant complications.
Virmani et al816The increasing numbers of targeted agents for the
treatment of CTCL, notably HDAC inhibitors,
including vorinostat,49,50 and romidepsin,51,52
brentuximab vedotin,53 and various immune
checkpoint inhibitors should be incorporated into
transplant protocols either in conditioning regi-
mens or as maintenance strategies. Selection of
the appropriate patient for allogeneic stem cell
transplant remains challenging, and guidelines
are needed for the treating physicians for appro-
priate referrals to specialized transplant centers.
Autologous transplant in the setting of therapeutic
advances, particularly immune modulation, should
be revisited as a potential therapeutic approach
because of its low risk for complications.REFERENCES
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